Pancreatic Cancer Research

ResearcherMayo Clinic in FloridaActive in the last 2 years

Jens Thomas Siveke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8772-4778; OpenAlex author ID A5033381769, A5071888326. Sources: OpenAlex.

Their work

Papers
117 (first author 6, last author 28)
Trials
0
Grants
0
Labs led
3
Collaborators
408
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 4 papers · 2014: 8 papers · 2015: 5 papers · 2016: 6 papers · 2017: 9 papers · 2018: 5 papers · 2019: 10 papers · 2020: 6 papers · 2021: 10 papers · 2022: 9 papers · 2023: 14 papers · 2024: 9 papers · 2025: 10 papers · 2026: 7 papers

Papers 50 of 117

  1. Contrastive virtual staining enhances deep learning-based PDAC subtyping from H&E-stained tissue cores. Co-author DOI 10.1002/path.6491↗
  2. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Co-author DOI 10.1016/j.esmogo.2025.100274↗
  3. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41467-026-69013-y↗
  4. Pancreatic cancer. Co-author DOI 10.1038/s41572-026-00699-6↗
  5. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Last author DOI 10.1038/s41591-026-04234-8↗
  6. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Co-author DOI 10.1093/oncolo/oyag023↗
  7. Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer Co-author DOI 10.64898/2026.10.06.756936↗
  8. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  9. Correction to: Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine‑induce… Co-author DOI 10.1007/s00259-025-07195-1↗
  10. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.celrep.2025.115541↗
  11. 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing? Co-author DOI 10.1016/j.esmogo.2025.100218↗
  12. Author Correction: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08979-z↗
  13. Transcription factor switching drives subtype-specific pancreatic cancer. Co-author DOI 10.1038/s41588-025-02389-7↗
  14. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response. Co-author DOI 10.1038/s44320-025-00085-6↗
  15. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatm… Co-author DOI 10.1186/s12885-025-13573-7↗
  16. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Co-author DOI 10.1186/s12943-025-02406-7↗
  17. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  18. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Co-author DOI 10.1007/s12094-023-03323-1↗
  19. Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study. Co-author DOI 10.1016/j.esmoop.2023.102219↗
  20. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Co-author DOI 10.1016/j.esmoop.2024.102944↗
  21. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  22. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  23. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  24. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Last author DOI 10.1038/s41591-024-03054-y↗
  25. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Last author DOI 10.1186/s13148-024-01623-z↗
  26. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. Co-author DOI 10.2967/jnumed.123.266262↗
  27. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer. Last author DOI 10.1016/j.esmoop.2023.101539↗
  28. Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acs.molpharmaceut.3c00453↗
  29. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05728-y↗
  30. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study P… Co-author DOI 10.1093/oncolo/oyad022↗
  31. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… Co-author DOI 10.1111/cts.13661↗
  32. Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription. Co-author DOI 10.1126/sciadv.adg5109↗
  33. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype. Co-author DOI 10.1136/gutjnl-2021-326550↗
  34. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-328154↗
  35. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth. Co-author DOI 10.1158/1078-0432.ccr-22-0794↗
  36. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  37. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  38. Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols. Co-author DOI 10.1159/000529452↗
  39. 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial. Last author DOI 10.2967/jnumed.122.264827↗
  40. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Co-author DOI 10.3390/curroncol30060436↗
  41. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  42. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascular… Co-author DOI 10.1007/s00259-022-05930-6↗
  43. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  44. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  45. Multimodal survival prediction in advanced pancreatic cancer using machine learning. Co-author DOI 10.1016/j.esmoop.2022.100555↗
  46. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  47. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Last author DOI 10.1038/s41467-021-27088-9↗
  48. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer. Co-author DOI 10.1080/2162402x.2022.2043037↗
  49. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s40170-022-00298-5↗
  50. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. Co-author DOI 10.1002/gcc.22932↗

Closest collaborators

The 25 strongest of 408 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marija Trajkovic‐Arsic · 30 shared papers, 2012–2026 · strength 3.37
  2. Rickmer Braren · 26 shared papers, 2013–2026 · strength 2.80
  3. Phyllis F. Cheung · 15 shared papers, 2018–2026 · strength 1.96
  4. Stefan Hubert Boeck · 17 shared papers, 2013–2026 · strength 1.92
  5. Volker Heinemann · 14 shared papers, 2013–2026 · strength 1.57
  6. Iréne Esposito · 18 shared papers, 2012–2026 · strength 1.39
  7. Stephan A. Hahn · 11 shared papers, 2015–2026 · strength 1.36
  8. Volker Kunzmann · 10 shared papers, 2015–2026 · strength 1.32
  9. Hana Algül · 10 shared papers, 2019–2026 · strength 1.31
  10. Roland Michael Schmid · 17 shared papers, 2011–2026 · strength 1.28
  11. Thomas Jens Ettrich · 9 shared papers, 2018–2026 · strength 1.26
  12. Elisabeth Heßmann · 12 shared papers, 2014–2026 · strength 1.24
  13. Irina Heid · 12 shared papers, 2011–2026 · strength 1.15
  14. Wilko Weichert · 10 shared papers, 2019–2025 · strength 1.14
  15. Laura Godfrey · 7 shared papers, 2021–2026 · strength 1.12
  16. Sven‐Thorsten Liffers · 8 shared papers, 2018–2026 · strength 1.01
  17. Frank Kullmann · 8 shared papers, 2015–2026 · strength 1.01
  18. Smiths Lueong · 7 shared papers, 2020–2025 · strength 0.93
  19. Uwe Pelzer · 8 shared papers, 2017–2025 · strength 0.93
  20. Georgios A. Kaissis · 8 shared papers, 2019–2025 · strength 0.90
  21. Teresa Mercade Macarulla · 7 shared papers, 2018–2026 · strength 0.89
  22. Dirk Waldschmidt · 6 shared papers, 2021–2024 · strength 0.86
  23. Barbara T. Grünwald · 5 shared papers, 2016–2026 · strength 0.85
  24. Michael Haas · 9 shared papers, 2013–2024 · strength 0.82
  25. Steven A. Johnsen · 7 shared papers, 2017–2024 · strength 0.77

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.